Du Pont Merck Pharmaceutical has named Richard Dolighan as president of its radiopharmaceuticals division in Billerica, MA. Dolighan most recently served as group vice president and general manager of North America for ICN Pharmaceuticals of Costa Mesa,
Du Pont Merck Pharmaceutical has named Richard Dolighan as president of its radiopharmaceuticals division in Billerica, MA. Dolighan most recently served as group vice president and general manager of North America for ICN Pharmaceuticals of Costa Mesa, CA. Dolighan replaces Kenneth Kasses as head of the Du Pont division.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.